Blocking the CD47–SIRPa interaction then promotes phagocytosis and PrCR (26, 28, 65, 66, 67), and in atherosclerosis it enhances phagocytic removal of diseased vascular cells and halts disease progression (68). Here, SIRPA is linked to atherosclerosis.